


IFW

AF/1649



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Washington, DC 22313-1450, on the date shown below.  
Dated: October 18, 2005  
Signature: *Katherine L. Neville*  
Katherine L. Neville

Docket No.: 01017/36667  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Banks, W.

Application No.: 10/049,182

Group Art Unit: 1649

Filed: June 19, 2002

Examiner: Kolker, D.

For: Modulation of the Blood-Brain Barrier  
Transporter for Leptin

**RESPONSE PURSUANT TO 37 CFR §1.11**

**MS After Final**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is filed in response to a Final Office Action (hereinafter "the Action"), mailed August 18, 2005 in the above-referenced application, wherein pending claims 1-5 were variously rejected under 35 U.S.C. §112, first paragraph, for assertedly lacking written description and enablement, and under 35 U.S.C. § 103(a) as assertedly obvious in view of Banks et al. (*Peptides*, 17:305-11, 1996) (hereinafter "Banks") further in view of Borges (*Eur. J Pharmacology* 269:243-48, 1994) (hereinafter "Borges") and Caro et al. (*Lancet* 348:159-61, ) (hereinafter "Caro"). Reconsideration is requested in light of the following amendments and remarks.

This response is due on October 18, 2005 without resort to the provisions of 37 C.F.R. §1.136, and is timely filed two-months after receipt of the Final Action.

**Amendments to the claims** are reflected in the claims set beginning on page 3 of this

paper.

**Remarks begin on page 11 of this paper.**